Chronic obstructive pulmonary disease (COPD) is a major cause of disability and death worldwide. People with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. Recently, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function in cardiac magnetic resonance imaging (MRI) or two-dimensional cardiac ultrasound for the assessments. The aim of this study is to specify the state of respiratory and cardiovascular systems as well as exercise capacity and quality of life in patients with newly diagnosed moderate-to-severe COPD and to evaluate their changes after short-term treatment with dual bronchodilation. We hypothesize that patients with newly diagnosed COPD and no previous records of cardiac diseases and no apparent signs of heart failure have significantly impaired cardiac autonomic integrity that precedes to increased risk of cardiovascular events. It is believed that cardiac autonomic integrity might significantly improve with dual bronchodilation therapy.
Study Type
OBSERVATIONAL
Enrollment
80
Lithuanian University of Health Sciences
Kaunas, Lithuania
RECRUITINGChange from baseline in cardiopulmonary exercise testing at week 12
The effect of dual bronchodilation on cardiopulmonary exercise test results in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in health-related quality of life at week 12
The effect of dual bronchodilation on health related quality of life (evaluating using the Short Form 36 Health Survey (SF-36) Questionnaire) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in forced expiratory volume in 1 second at week 12
The effect of dual bronchodilation on forced expiratory volume in 1 second (FEV1) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in forced vital capacity at week 12
The effect of dual bronchodilation on forced vital capacity (FVC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in diffusing capacity of the lungs for carbon monoxide at week 12
The effect of dual bronchodilation on diffusing capacity of the lungs for carbon monoxide (DLCO) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in residual volume at week 12
The effect of dual bronchodilation on residual volume (RV) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in residual volume to total lung capacity ratio at week 12
The effect of dual bronchodilation on residual volume to total lung capacity ratio (RV/TLC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in forced residual capacity to total lung capacity ratio at week 12
The effect of dual bronchodilation on forced residual capacity to total lung capacity ratio (FRC/TLC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease
Time frame: Baseline and week 12
Change from baseline in right ventricle end-systolic volume index at week 12
The effect of dual bronchodilation on right ventricle end-systolic volume index (RVESVi) in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in right ventricle end-diastolic volume index at week 12
The effect of dual bronchodilation on right ventricle end-diastolic volume index (RVEDVi) in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in on left ventricle end-systolic volume index at week 12
The effect of dual bronchodilation on left ventricle end-systolic volume index (LVESVi) in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in left ventricle end-diastolic volume index at week 12
The effect of dual bronchodilation on left ventricle end-diastolic volume index (LVEDVi) in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in stroke volume index at week 12
The effect of dual bronchodilation on stroke volume index (SVi) in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in right ventricular strains at week 12
The effect of dual bronchodilation on right ventricular strains in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in washout rate at week 12
The effect of dual bronchodilation on washout rate (WR) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in heart to mediastinum ratio at week 12
The effect of dual bronchodilation on early and late heart to mediastinum ratio (HMR) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Change from baseline in left ventricle total defect score at week 12
The effect of dual bronchodilation on early and late left ventricle early total defect score (TDS) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD
Time frame: Baseline and week 12
Differences in health-related quality of life between COPD and non-COPD individuals
Time frame: Baseline
Differences in exercise capacity between COPD and non-COPD individuals
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.